Literature DB >> 18241251

The changing pattern of kidney cancer incidence and mortality in Europe.

Fabio Levi1, Jacques Ferlay, Carlotta Galeone, Franca Lucchini, Eva Negri, Peter Boyle, Carlo La Vecchia.   

Abstract

OBJECTIVE: To update trends in kidney cancer mortality in 32 European countries and the European Union (EU) as a whole, as mortality from kidney cancer has increased throughout Europe until the late 1980s or early 1990s, and has tended to stabilise or decline thereafter.
METHODS: Data from the World Health Organization mortality database over the period 1980-2004 were used to compute age-specific and age-standardized (world standard) rates per 100,000 persons at all ages, and truncated to 35-64 years.
RESULTS: In men in the EU, mortality rates from kidney cancer peaked at 4.8 per 100,000 in 1990-1994, and declined to 4.1 (-13%) in 2000-2004. In women in the EU, the corresponding values were 2.1 in 1990-1994 and 1.8 (-17%) in 2000-2004. The main decreases were in Scandinavian countries, and other western European countries. In most eastern European countries kidney mortality rates tended to stabilise, even if values remained high, especially in the Czech Republic and Baltic countries. For kidney cancer incidence, there were decreases in rates for both sexes in Sweden throughout the 25-year calendar period considered. In the last 10 years considered, incidence rates decreased or tended to stabilise also in other northern European countries in both sexes, except in the UK.
CONCLUSION: The present work confirms and further quantifies the recent favourable trends in kidney cancer mortality and (to a lesser degree) in incidence across most European countries. Thus, improvements in diagnosis and treatments cannot largely explain the declines in mortality. Apart from a favourable role of reduced tobacco smoking in men, the interpretation of these trends remains undefined.

Entities:  

Mesh:

Year:  2008        PMID: 18241251     DOI: 10.1111/j.1464-410X.2008.07451.x

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


  60 in total

Review 1.  Comparing how significantly the pharmacological treatment of genitourinary cancer in a non-curative setting affects endpoints of survival or response.

Authors:  David R Yates; Morgan Rouprêt
Journal:  World J Urol       Date:  2011-11-23       Impact factor: 4.226

Review 2.  [Metastasectomy for renal cell cancer].

Authors:  B Brehmer; C Piper; D Pfister; D Porres; A Heidenreich
Journal:  Urologe A       Date:  2012-09       Impact factor: 0.639

3.  Clinical evaluation and technical features of three-dimensional laparoscopic partial nephrectomy with selective segmental artery clamping.

Authors:  Yuan Ruan; Xiao-Hai Wang; Kui Wang; Yu-Yang Zhao; Shu-Jie Xia; Dong-Liang Xu
Journal:  World J Urol       Date:  2015-08-29       Impact factor: 4.226

4.  Trends in Renal-Cell Carcinoma Incidence and Mortality in the United States in the Last 2 Decades: A SEER-Based Study.

Authors:  Anas M Saad; Mohamed M Gad; Muneer J Al-Husseini; Inas A Ruhban; Mohamad Bassam Sonbol; Thai H Ho
Journal:  Clin Genitourin Cancer       Date:  2018-10-11       Impact factor: 2.872

5.  MiR-16 family as potential diagnostic biomarkers for cancer: a systematic review and meta-analysis.

Authors:  Jianxiong Cui
Journal:  Int J Clin Exp Med       Date:  2015-02-15

6.  Incidence of renal carcinoma in non-functioning kidney due to renal pelvic stone disease.

Authors:  Kursad Zengin; Serhat Tanik; Nevzat Can Sener; Sebahattin Albayrak; Musa Ekici; Ibrahim Halil Bozkurt; Hasan Bakirtas; Mesut Gurdal; Muhammed Abdurrahim Imamoglu
Journal:  Mol Clin Oncol       Date:  2015-04-24

Review 7.  Precision medicine from the renal cancer genome.

Authors:  Yasser Riazalhosseini; Mark Lathrop
Journal:  Nat Rev Nephrol       Date:  2016-10-03       Impact factor: 28.314

8.  Arterial Clamping Increases Central Renal Cryoablation Efficacy: An Animal Study.

Authors:  Lasse L Nonboe; Tommy K Nielsen; Søren Høyer; Ole Graumann; Jørgen Frøkiær; Michael Borre
Journal:  Technol Cancer Res Treat       Date:  2016-08-25

9.  Targeted therapies in the management of renal cell carcinoma: role of bevacizumab.

Authors:  Bernard Escudier; Jan Cosaert; Sangeeta Jethwa
Journal:  Biologics       Date:  2008-09

10.  An analysis of growth, differentiation and apoptosis genes with risk of renal cancer.

Authors:  Linda M Dong; Paul Brennan; Sara Karami; Rayjean J Hung; Idan Menashe; Sonja I Berndt; Meredith Yeager; Stephen Chanock; David Zaridze; Vsevolod Matveev; Vladimir Janout; Hellena Kollarova; Vladimir Bencko; Kendra Schwartz; Faith Davis; Marie Navratilova; Neonila Szeszenia-Dabrowska; Dana Mates; Joanne S Colt; Ivana Holcatova; Paolo Boffetta; Nathaniel Rothman; Wong-Ho Chow; Philip S Rosenberg; Lee E Moore
Journal:  PLoS One       Date:  2009-03-24       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.